» Articles » PMID: 35867708

The Effects of Biological Sex and Cardiovascular Disease on COVID-19 Mortality

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiovascular disease (CVD) is a common comorbidity observed in patients with coronavirus disease 2019 (COVID-19), which is associated with increased severity and mortality. However, the effects of biological sex on CVD-associated mortality in patients with COVID-19 are poorly established, particularly among Hispanic/Latin Americans. We examined the association of preexisting CVD with COVID-19 mortality in hospitalized Latin American men and women. This multicenter study included Mexican patients hospitalized with a positive diagnosis of COVID-19. The main outcome was in-hospital mortality. Multivariable regression analyses were used to calculate the adjusted odds ratio with 95% confidence interval for mortality in women and men. Of 81,400 patients with a positive diagnosis for SARS-CoV-2 infection, 28,929 (35.54%) hospitalized patients were evaluated. Of these, 35.41% (10,243) were women. In-hospital death was higher in men than in women. In relation to CVD between the sexes, women had a higher incidence of CVD than men (4.69 vs. 3.93%, = 0.0023). The adjusted logistic regression analyses showed that CVD was significantly associated with COVID-19 mortality in women but not men. We then stratified by sex according to age <52 and ≥52 yr old. Similar significant association was also found in prespecified analysis in women ≥52 yr old but not in men of similar age. We conclude that CVD's effect on mortality among patients hospitalized with COVID-19 is dependent on biological sex and age in this Latin American cohort. These results suggest that therapeutic strategies for Latin American women with CVD and COVID-19 should include particular attention to their cardiovascular health. CVD's effect on COVID-19 mortality is dependent on biological sex and age. CVD in women but not men with COVID-19 is associated with significantly unfavorable outcomes.

Citing Articles

Associations between pre-existing comorbidities and in-hospital cardiovascular events and mortality among COVID-19 patients in Bangladesh: a secondary analysis of a prospective cohort study.

Islam F, Salahin K, Chowdhury A, Amin M, Rahim A, Akter S BMJ Open. 2024; 14(8):e083982.

PMID: 39645266 PMC: 11367314. DOI: 10.1136/bmjopen-2024-083982.


Risk of Early Postoperative Cardiovascular and Cerebrovascular Complication in Patients with Preoperative COVID-19 Undergoing Cancer Surgery.

SenthilKumar G, Verhagen N, Nimmer K, Yang X, Castro C, Szabo A J Am Coll Surg. 2024; 238(6):1085-1097.

PMID: 38348959 PMC: 11330174. DOI: 10.1097/XCS.0000000000001039.


Sex as a biological variable for cardiovascular physiology.

Lindsey M, Usselman C, Ripplinger C, Carter J, DeLeon-Pennell K Am J Physiol Heart Circ Physiol. 2023; 326(3):H459-H469.

PMID: 38099847 PMC: 11219053. DOI: 10.1152/ajpheart.00727.2023.


Preoperative SARS-CoV-2 infection increases risk of early postoperative cardiovascular complications following noncardiac surgery.

SenthilKumar G, Verhagen N, Sheriff S, Yang X, Castro C, Szabo A Am J Physiol Heart Circ Physiol. 2023; 324(6):H721-H731.

PMID: 36930659 PMC: 10151044. DOI: 10.1152/ajpheart.00097.2023.


New developments in translational microcirculatory research.

SenthilKumar G, Gutierrez-Huerta C, Freed J, Beyer A, Fancher I, LeBlanc A Am J Physiol Heart Circ Physiol. 2022; 323(6):H1167-H1175.

PMID: 36306213 PMC: 9678417. DOI: 10.1152/ajpheart.00566.2022.


References
1.
El Khoudary S, Aggarwal B, Beckie T, Hodis H, Johnson A, Langer R . Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020; 142(25):e506-e532. DOI: 10.1161/CIR.0000000000000912. View

2.
Ogedegbe G, Ravenell J, Adhikari S, Butler M, Cook T, Francois F . Assessment of Racial/Ethnic Disparities in Hospitalization and Mortality in Patients With COVID-19 in New York City. JAMA Netw Open. 2020; 3(12):e2026881. PMC: 7718605. DOI: 10.1001/jamanetworkopen.2020.26881. View

3.
Woodward M . Cardiovascular Disease and the Female Disadvantage. Int J Environ Res Public Health. 2019; 16(7). PMC: 6479531. DOI: 10.3390/ijerph16071165. View

4.
Daviglus M, Talavera G, Aviles-Santa M, Allison M, Cai J, Criqui M . Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. JAMA. 2012; 308(17):1775-84. PMC: 3777250. DOI: 10.1001/jama.2012.14517. View

5.
Fagyas M, Banhegyi V, Uri K, Enyedi A, Lizanecz E, Manyine I . Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. Geroscience. 2021; 43(5):2289-2304. PMC: 8529378. DOI: 10.1007/s11357-021-00467-2. View